Tasimelteon
|
|
|
- CAS-Nr.
- 609799-22-6
- Englisch Name:
- Tasimelteon
- Synonyma:
- MA 1;VEC 162;BMS 214778;asimelteon;tasimelteon;Tasimalteon;Tasimelteon-d5;TasiMelteon/BMS214778;tasimelteon impurity A;Tasimelteon(VEC-162,Hetlioz )
- CBNumber:
- CB41518537
- Summenformel:
- C15H19NO2
- Molgewicht:
- 245.32
- MOL-Datei:
- 609799-22-6.mol
|
Tasimelteon Eigenschaften
- Schmelzpunkt:
- 78 °C
- Siedepunkt:
- 442.6±24.0 °C(Predicted)
- Dichte
- 1.145
- storage temp.
- 2-8°C
- Löslichkeit
- Chloroform (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 16.43±0.46(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H336 |
Kann Schläfrigkeit und Benommenheit verursachen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Schläfrigkeit und Benommenheit) |
Warnung |
|
P261, P271, P304+P340, P312,P403+P233, P405, P501 |
| H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Tasimelteon Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Tasimelteon, which is marketed by Vanda Pharmaceuticals as
Hetlioz and developed in partnership with Bristol-Myers Squibb,
is a drug that was approved by the US FDA in January 2014 for
the treatment of non-24-hour sleep–wake disorder (also called
Non-24, N24 and N24HSWD). Tasimelteon is a melatonin MT1
and MT2 receptor agonist; because it exhibits a greater affinity to
the MT2 receptor than MT1, is also known as Dual Melatonin
Receptor Agonist.234 Two randomized controlled trials (phases II
and III) demonstrated that tasimelteon improved sleep latency
and maintenance of sleep with a shift in circadian rhythms, and
therefore has the potential to treat patients with transient insomnia
associated with circadian rhythm sleep disorders. Preclinical
studies showed that the drug has similar phase-shifting properties
to melatonin, but with less vasoconstrictive effects.
Verwenden
Tasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.
Definition
ChEBI: A member of the class of 1-benzofurans that is propionamide in which one of the amide hydrogens is replaced by a [(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl group. A melatonin receptor agonist used for the
treatment of non-24-hour sleep-wake disorder.
Tasimelteon Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Tasimelteon Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 146)Lieferanten
609799-22-6()Verwandte Suche:
- Tasimelteon (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
- tasimelteon impurity A
- tasimelteon
- (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
- BMS 214778
- MA 1
- VEC 162
- TasiMelteon/BMS214778
- Tasimalteon
- Tasimelteon-d5
- N-[[(1R,2R)-2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
- Tasimelteon(VEC-162,Hetlioz )
- Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]-
- N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide
- asimelteon
- 609799-22-6
- Pharmaceuticals
